Some older women with common breast cancer can skip adjuvant chemo

Reuters Health - 09/12/2020 - Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with one to three positive lymph nodes and a low risk of recurrence can safely forego adjuvant chemotherapy, according to the first results of the RxPONDER trial. This finding is expected to save "tens of thousands of postmenopausal women the time, expense and potentially harmful side effects that can be associated with chemotherapy infusions," said Dr. Kevin Kalinsky, with the Winship Cancer Institute of Emory University, in Atlanta, during a media briefing at the virtual 2020 San Antonio Breast Cancer Symposium (SABCS). In contrast to postmenopausal women, premenopausal women with positive nodes do benefit significantly from chemotherapy, the results suggest. The RxPONDER trial follows the "landmark" TAILORx trial, which demonstrated that postmenopausal women with lymph node-negative, HR-positive, HER...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 9 December, 202015 December, 2020